Drug Information

Drug General Information
Drug ID
D03ZJE
Former ID
DNC001089
Drug Name
PAI-1
Drug Type
Small molecular drug
Indication Discovery agent Phase 4 [522460]
Formula
C16H27NO4
Canonical SMILES
CCCCCCCCCC(=O)CC(=O)NC1CCOC1=O
InChI
1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)
InChIKey
PHSRRHGYXQCRPU-UHFFFAOYSA-N
PubChem Compound ID
127864
PubChem Substance ID
14002, 10241879, 14873627, 29307045, 52169859, 57342355, 103640299, 104366800, 123058754, 125335308, 125569363, 128917720, 135082566, 142062025, 204364836, 223661376, 235415351
Target and Pathway
Target(s) Urokinase-type plasminogen activator Target Info Inhibitor [537833]
KEGG Pathway NF-kappa B signaling pathway
Complement and coagulation cascades
Transcriptional misregulation in cancer
Proteoglycans in cancer
MicroRNAs in cancer
NetPath Pathway IL2 Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Blood coagulation
Plasminogen activating cascade
CCKR signaling map ST
Pathway Interaction Database Beta1 integrin cell surface interactions
E2F transcription factor network
Beta3 integrin cell surface interactions
Osteopontin-mediated events
Validated transcriptional targets of AP1 family members Fra1 and Fra2
amb2 Integrin signaling
ATF-2 transcription factor network
AP-1 transcription factor network
Beta2 integrin cell surface interactions
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
FGF signaling pathway
Reactome Dissolution of Fibrin Clot
WikiPathways DNA Damage Response (only ATM dependent)
Senescence and Autophagy in Cancer
Complement and Coagulation Cascades
Endochondral Ossification
Wnt Signaling Pathway
Wnt Signaling Pathway and Pluripotency
Blood Clotting Cascade
Dissolution of Fibrin Clot
Osteopontin Signaling
References
Ref 522460ClinicalTrials.gov (NCT00770328) The Effects of Pentoxifylline on PAI-1 in an Obese Population. U.S. National Institutes of Health.
Ref 537833Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.